Heartflow (NASDAQ:HTFL) Stock Rating Upgraded by UBS Group

Heartflow (NASDAQ:HTFL) was upgraded by investment analysts at UBS Group to a “hold” rating in a research report issued on Wednesday, Zacks reports.

A number of other equities analysts have also recently commented on the stock. Robert W. Baird set a $45.00 target price on shares of Heartflow in a report on Friday, August 14th. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (up from $38.00) on shares of Heartflow in a research note on Friday, August 14th. JPMorgan Chase & Co. lifted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Wells Fargo & Company increased their target price on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.88.

Heartflow Stock Up 9.7%

Shares of NASDAQ HTFL opened at $49.88 on Wednesday. The stock has a market cap of $4.34 billion and a PE ratio of -27.26. Heartflow has a 52-week low of $20.13 and a 52-week high of $51.78. The business has a 50-day moving average price of $35.52 and a 200 day moving average price of $30.78.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company had revenue of $64.08 million for the quarter. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. Sell-side analysts anticipate that Heartflow will post -0.75 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total value of $380,099.37. Following the completion of the sale, the insider owned 86,459 shares in the company, valued at $3,564,704.57. This trade represents a 9.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 6,640 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $50.03, for a total transaction of $332,199.20. Following the sale, the chief financial officer directly owned 214,503 shares in the company, valued at approximately $10,731,585.09. This represents a 3.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 208,765 shares of company stock worth $8,444,106. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Heartflow

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. acquired a new stake in shares of Heartflow in the 3rd quarter worth approximately $48,871,000. Legal & General Group Plc purchased a new stake in Heartflow during the third quarter worth $59,000. Franklin Resources Inc. purchased a new stake in Heartflow during the third quarter worth $10,829,000. UBS Group AG acquired a new stake in Heartflow in the third quarter valued at $5,130,000. Finally, Sei Investments Co. purchased a new position in shares of Heartflow in the third quarter valued at $303,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).